Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America (MBAA) ...

Voluntary MFN commitments by 16 manufacturers reportedly cover ~70% of Medicare drug spending, potentially obviating GUARD/GLOBE finalization while avoiding predictable legal challenges. Lindsay ...

Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar. The panelists were Lindsay Bealor Greenleaf, JD, MBA, head of market access policy ...

The Centers for Medicare & Medicaid Services (CMS) in the US has extended the deadline for companies to take part in its ...

The congress opened with a plenary session that discussed and debated how to decode current disruptions seen in pharmaceutical markets globally.

The implementation of the Most Favored Nation (MFN) pricing and the introduction of the GENEROUS model in U.S. Medicaid present opportunities for pharmaceutical companies to align with international ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...

OptimizeRx Corp OPRX shares are tumbling on Friday as the company faces increased market volatility and uncertainty surrounding Most Favored Nation (MFN) pricing. Earnings Exceed Expectations The ...